Description
Semax is a synthetic heptapeptide consisting of the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow as a synthetic fragment derived from the N-terminal region of ACTH (adrenocorticotropic hormone, residues 4-10) with a Pro-Gly-Pro C-terminal extension for peptidase resistance. As an ACTH-derived peptide, Semax has been investigated for melanocortin receptor binding (MC3R, MC4R, MC5R) and BDNF gene expression endpoints in preclinical research literature (Myasoedov, Levitskaya, Andreeva, and colleagues). The compound is one of the most-studied Russian-origin neuropeptides and serves as the comparator compound for stabilized analogs including N-Acetyl Semax (with N-terminal acetylation for further peptidase protection). Semax is studied here primarily as a research tool for ACTH-derived peptide pharmacology and structure-activity relationship (SAR) studies of N-terminal peptide modifications.
Benefits (Research Focus)
• Melanocortin receptor pharmacology — studied for MC3R, MC4R, and MC5R receptor binding activity as an ACTH-derived peptide
• BDNF pathway research — investigated for hippocampal BDNF gene expression endpoints in rodent research models
• Transcriptomic research — explored for gene expression panel effects in CNS cell research models
• Peptide pharmacology research — examined for receptor binding profiles and SAR studies of ACTH-derived heptapeptides
• Comparative SAR research — researched alongside N-Acetyl Semax for comparative N-terminal modification studies
What Researchers Look At
• Melanocortin receptor binding affinity and selectivity profiles across MC3R / MC4R / MC5R subtypes
• Hippocampal BDNF gene and protein expression in rodent research models
• Transcriptomic gene expression panels in CNS cell research
• Plasma half-life and peptidase stability characterization
• Comparative pharmacology versus N-Acetyl Semax and other ACTH-derived research peptides
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 10 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Semax
• Synonyms: MEHFPGP; ACTH(4-10) extended analog; Russian ACTH-derived heptapeptide research compound
• Class: Synthetic heptapeptide; ACTH-derived peptide; Russian-origin neuropeptide research compound
• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) — 7 amino acids
• Origin: Institute of Molecular Genetics, Russian Academy of Sciences (Moscow); synthesized as an ACTH(4-10) analog with C-terminal Pro-Gly-Pro extension
• Formula / M.W.: C37H51N9O10S, ~813.92 g/mol
• CAS: 80714-61-0
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• Semax Janoshik Verification — October 3, 2025
• Semax Janoshik Verification — June 15, 2026
• Semax Janoshik Verification — July 30, 2026 – Batch# SX07-1010
